on Carl Zeiss Meditec AG (isin : DE0005313704)
Carl Zeiss Meditec Faces Revenue Decline Amidst Challenging Fiscal Year
Carl Zeiss Meditec AG reported a slight revenue drop for fiscal year 2023/24, registering €2,066.1m compared to the previous year's €2,089.3m. The company's adjusted EBIT was €245.9m, aligning with the forecast of €225-275m. The decline was influenced by a restrictive investment climate and lower consumer confidence globally.
The Ophthalmology Strategic Business Unit saw modest growth, primarily driven by the DORC acquisition, while the Microsurgery unit experienced a 7% decline. EMEA regions witnessed double-digit growth, contrasted by revenue decreases in the Americas and APAC, particularly dampened by high interest rates and health policy uncertainties.
The EBIT margin dropped to 9.4% from 16.7% due to unfavorable product mix and reduced demand. Despite challenges, Carl Zeiss Meditec remains cautiously optimistic about stabilizing EBITA and revenue growth with new product launches and public investment opportunities in 2024/25.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Carl Zeiss Meditec AG news